208 related articles for article (PubMed ID: 36945884)
1. DNA hypomethylation mediates immune response in pan-cancer.
Zhang C; Sheng Q; Zhao N; Huang S; Zhao Y
Epigenetics; 2023 Dec; 18(1):2192894. PubMed ID: 36945884
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy.
Park C; Jeong K; Park JH; Jung S; Bae JM; Kim K; Ock CY; Kim M; Keam B; Kim TM; Jeon YK; Lee SH; Lee JS; Kim DW; Kang GH; Chung DH; Heo DS
Cancer Immunol Immunother; 2021 Jun; 70(6):1605-1617. PubMed ID: 33230567
[TBL] [Abstract][Full Text] [Related]
3. LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.
Luo L; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Hong S
Front Immunol; 2023; 14():959868. PubMed ID: 36798137
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract][Full Text] [Related]
7. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
8. Methylation of immune synapse genes modulates tumor immunogenicity.
Berglund A; Mills M; Putney RM; Hamaidi I; Mulé J; Kim S
J Clin Invest; 2020 Feb; 130(2):974-980. PubMed ID: 31714899
[TBL] [Abstract][Full Text] [Related]
9. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.
Park SY; Seo AN; Jung HY; Gwak JM; Jung N; Cho NY; Kang GH
PLoS One; 2014; 9(6):e100429. PubMed ID: 24971511
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analysis of the DNA methylation patterns of long non-coding RNA.
Wang S; Wang R; Gao F; Huang J; Zhao X; Li D
Genomics; 2022 Jul; 114(4):110377. PubMed ID: 35513292
[TBL] [Abstract][Full Text] [Related]
11. DNA Methylation: From Cancer Biology to Clinical Perspectives.
Chen C; Wang Z; Ding Y; Wang L; Wang S; Wang H; Qin Y
Front Biosci (Landmark Ed); 2022 Dec; 27(12):326. PubMed ID: 36624943
[TBL] [Abstract][Full Text] [Related]
12. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
[TBL] [Abstract][Full Text] [Related]
13. Distinct functional patterns of gene promoter hypomethylation and hypermethylation in cancer genomes.
Shen X; He Z; Li H; Yao C; Zhang Y; He L; Li S; Huang J; Guo Z
PLoS One; 2012; 7(9):e44822. PubMed ID: 22970311
[TBL] [Abstract][Full Text] [Related]
14. Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics.
Zhong F; Lin Y; Zhao L; Yang C; Ye Y; Shen Z
Br J Cancer; 2023 Jul; 129(1):24-37. PubMed ID: 37117649
[TBL] [Abstract][Full Text] [Related]
15. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
[TBL] [Abstract][Full Text] [Related]
16. ROS-mediated DNA methylation pattern alterations in carcinogenesis.
Wu Q; Ni X
Curr Drug Targets; 2015; 16(1):13-9. PubMed ID: 25585126
[TBL] [Abstract][Full Text] [Related]
17. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
18. Fc Fragment of IgE Receptor Ig (FCER1G) acts as a key gene involved in cancer immune infiltration and tumour microenvironment.
Yang R; Chen Z; Liang L; Ao S; Zhang J; Chang Z; Wang Z; Zhou Y; Duan X; Deng T
Immunology; 2023 Feb; 168(2):302-319. PubMed ID: 36054819
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.
McGuire MH; Herbrich SM; Dasari SK; Wu SY; Wang Y; Rupaimoole R; Lopez-Berestein G; Baggerly KA; Sood AK
EBioMedicine; 2019 May; 43():127-137. PubMed ID: 31056473
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma.
Luo H; Ye M; Hu Y; Wu M; Cheng M; Zhu X; Huang K
Aging (Albany NY); 2022 Sep; 14(19):7824-7850. PubMed ID: 36152044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
